Kornimate/medical-research-clean huggingface dataset:
evolve-mi: evolocumab very early after myocardial infarction

Conditions: Cardiovascular Disease; Myocardial Infarction; Stroke; Coronary Revascularization

Summary: the primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-st-segment elevation myocardial infarction \[nstemi\] and st-segment elevation myocardial infarction \[stemi\]).


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * hospitalized for primary reason of nstemi or stemi due to presumed atherosclerotic disease exclusion criteria: * participants requiring invasive hemodynamic and/or vasopressor/inotropic support at the time of screening * participants with elevated biomarkers of myocardial injury due to secondary/nonatherosclerotic etiology (eg, sepsis, atrial fibrillation, vasospasm, decompensated heart failure, uncontrolled hypertension, stress induced cardiomyopathy)

Keywords: acute myocardial infarction cardiovascular disease stroke coronary revascularization evolocumab stemi nstemi heart attack pragmatic
a study to evaluate the safety and efficacy of tacrolimus for lupus nephritis under actual use situations

Conditions: Lupus Nephritis

Summary: to evaluate the safety and efficacy of tacrolimus for lupus nephritis under actual-use.

the objectives of the survey are to evaluate the safety and efficacy of tacrolimus for lupus nephritis under actual-use situations, and to identify factors that might affect the safety and efficacy of tacrolimus. in addition, long-term renal outcome will be evaluated.

Eligibility criteria:
patients receiving tacrolimus for the treatment of lupus nephritis

Keywords: long-term treatment tacrolimus renal failure
let's play! healthy kids after cancer

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission; Obesity

Summary: this pilot study will evaluate the feasibility, acceptability, and potential efficacy of a parent-targeted, phone-based program to prevent unhealthy weight gain and improve biomarkers of oxidative stress and inflammation among childhood acute lymphoblastic leukemia survivors.

acute lymphoblastic leukemia (all) is the most common childhood cancer, accounting for 25% of all childhood malignancies. treatment of childhood all has a high success rate, with long-term event-free survival of \>85%. treatment success, however, has not come without cost. recognition of long-term health problems related to childhood cancer therapies is growing. both during and after therapy, children treated for all are at risk for fatigue, reduced physical activity, poor dietary intake, and excessive weight gain, which are driven by physiological (chemotherapy-induced) changes and social (home/environmental) factors. the goals of this pilot study are to evaluate the feasibility, acceptability, and potential efficacy of a parent-targeted, phone-delivered nutrition and physical activity program to prevent unhealthy weight gain among 60 childhood all survivors, 4-10 years of age. participants will be randomly assigned to either the phone-delivered parent-targeted nutrition and physical activity intervention or a standard-of-care control group. intervention success will be benchmarked by changes in key weight-related behaviors (physical activity and dietary intake) over the 6-month trial, and initial impact of the intervention on biomarkers of inflammation and oxidative stress, fatigue, and body composition will be examined.

Eligibility criteria:
inclusion criteria: * between 4.0 years and \< 11.0 years of age at the time of recruitment * previously diagnosed of all and currently in remission * between 1-5 years post completion of chemotherapy * bmi ≥ 85 percentile for age and sex (overweight or obese) or at risk for obesity (bmi between the 50th and 85th percentile and at least one overweight parent (bmi ≥ 25 kg/m2) exclusion criteria: * history of cranial radiation therapy * history of bone marrow transplant * history of relapse of all * diagnosis of down's syndrome * comorbidities of obesity that require immediate subspecialist referral * significant pulmonary, cardiovascular, orthopedic, or musculoskeletal problems that would, in their oncologist's judgment, limit their ability to participate in physical activity * significant psychiatric or neurologic disorders that would impair compliance with study protocol * current participation in a weight-loss program
effect of fenofibrate on endothelial function and high-density lipoproteins (hdl)in patients with coronary heart disease

Conditions: Coronary Heart Disease; Hyperlipidemia

Summary: fenofibrate is a drug that acts on the ppar alpha receptors, increasing hdl-cholesterol and decreasing triglyceride levels. the interaction with these receptors has antiatherogenic actions by regulating the expression con key proteins that participate in vascular inflammation, plaque stability and thrombosis. fenofibrate reduces triglycerides and increases hdl-c in plasma. it also decreases small, dense ldl particles. the use of this drug has resulted in improvement of vascular function measured by endothelial function. our hypotheses state that fenofibrate will improve: endothelial function, improve hdl antioxidant capacity and size distribution towards a predominance of small hdl particles.

patients with stable coronary heart disease, with ldl-c levels at goal will be invited to participate in this randomized, double blind study to receive either placebo or fenofibrate in addition to their statin therapy.

Eligibility criteria:
inclusion criteria: * male patients 18-60 years of age * stable coronary heart disease (no cardiovascular event 3 months prior to enrollment) * stable lipid-modifying drug therapy (previous 2 months) * low-dose statin therapy with ldl-c at goal (\< 100 mg/dl) * triglyceride levels 151-500 mg/dl * hdl-c levels \<40 mg/dl exclusion criteria: * diabetes mellitus * uncontrolled hypertension systolic blood pressure \>160 mmhg and/or diastolic blood pressure \>100 mmhg * subjects with renal (serum creatinine \>1.5 times the upper limit of normal (uln)), hepatobiliary (cholelithiasis, biliary cirrhosis, ast and/or alt \>2x uln) or active thyroid disease (tsh \>1.5x uln or \<0.05 uui/ml) * hypersensitivity to fenofibrate or to any other component of its formula * history of photoallergic reaction or phototoxicity to fenofibrate or ketoprofen

Keywords: fenofibrate coronary heart disease mixed hyperlipidemia
development of fluid intake app for management of fluid intake during hemodialysis

Conditions: Weight Gain

Summary: methods are needed to help decrease interdialytic weight gains in hemodialysis patients. one potential method for accomplishing this goal is to develop an app for smartphones that allow patients to track their fluid intake throughout the course of the day. this protocol is designed to test the safety and efficacy of this app, followed by use of the app in patients with large fluid weight gains between hd sessions. in the vanguard phase, patients without large interdialytic fluid gains (less than 4%) will use the app to to determine the association between the interdialytic weight gain and the fluid consumed as recorded by use of the app for each interdialytic period. the app will be modified, if needed, prior to initiation of the full scale trial.

for the vanguard phase of the trial, a survey will be used to assess the usability of the app as well as to collect recommendations for changes to the app itself (appendix one). for this vanguard phase study, the survey for participants will be designed to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of preselected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review). the survey for the study coordinator will be designed to assess the ease of reviewing data from participants and the perceived difficulty of patient use of the app.

Eligibility criteria:
inclusion criteria: * subject, upon briefing of the content of the present study, fully understanding and agreeing to its objective and having given written (dated and signed) informed consent form to take part in the study. * adult chronic hemodialysis patients who are at least 18 years of age * average interdialytic fluid gains of less than 4% of body weight for both weekdays and weekends for a 30 day period * access to a smartphone for use of the app and comfort with using apps on a regular basis * access to a smartphone running under either ios or android operating systems * sufficient knowledge and understanding of the english language to use the application available only in english (us) language * mental capacity to use and understand the fluid management app * willingness to share intake data collected with the research team exclusion criteria: * scheduled for a living related renal transplant in the next four months * class iii or iv heart failure * need for chronic oxygen therapy due to pulmonary disease * hospitalization within 30 days of entry into the study * current participation in a randomized clinical trial or in the exclusion period of another clinical trial

Keywords: hemodialysis fluid intake interdialytic weight gain
an investigation of biomarker candidate molecules in laryngeal carcinoma

Conditions: Larynx Cancer; Larynx Carcinoma

Summary: the aim of this study was to determine serum levels of vegf, svegfr1, vegfr2, igfbp-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value.

although there has been a significant increase in survival in many other cancer types through the years, no significant increase has been achieved in laryngeal scc survival rates in the last 50 years. despite the advancements in surgical techniques, organ preservation protocols and multidisciplinary approach, significant amount of patients have been living with morbidity or dying due to recurrence and metastasis. this lack of significant improvement in mortality rates creates the need for reliable and accurate biomarkers in early diagnosis, treatment and follow-up. considering that the prognosis of two patients at the same clinical stage and treated with the same treatment protocol may differ, it suggests that there may be some differences at the molecular level apart from clinical stages. this study was mainly prepared to determine serum levels of vegf, svegfr1, vegfr2, igfbp-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value. to reach these aims, 60 patients who were prospectively and consecutively recruited from those who admitted to hacettepe university, department of otorhinolaryngology, ankara, turkey, and were diagnosed with lscc between may 2018 and february 2020. 20 healthy and age-matched controls were chosen from the hospital staff and relatives of the patients. serum samples were obtained from all participants at the time of diagnosis, centrifuged and stored at -80 c. elisa method will be used to analyze the serum levels of vegf, svegfr1, vegfr2, igfbp-3, angiogenin and endoglin. data analysis will reveal if there are any association between biomarker candidate molecules and clinical parameters.

Eligibility criteria:
inclusion criteria: * 60 male or female patients with a newly diagnosed laryngeal squamous cell carcinoma * patients without any previous history of laryngeal carcinoma * 20 healthy, age- and sex- matched controls exclusion criteria: * previous history of laryngeal squamous cell carcinoma * having comorbid systemic diseases like dm, hypertension, cardiologic or rheumatologic diseases * having malign tumors elsewhere * history of chemotherapy/radiotherapy.

Keywords: larynx carcinoma angiogenin endoglin vegf svegfr-1 vegfr-2 osteoponitn biomarker
a proof-of-concept study of ac-201 controlled-release tablet (cr tablet) in patients with hemophilic arthropathy

Conditions: Hemophilic Arthropathy

Summary: repeated joint bleeding leads to hemophilic arthropathy (ha), which manifests with chronic synovitis, cartilage damage and bony destruction. currently available treatments of ha, including analgesics, nsaids, and hyaluronic acid, are predominantly directed toward the symptomatic relief of pain and inflammation, with no or little effect on joint cartilage degeneration. ac201cr, a control released formulation of ac-201, demonstrates anti-inflammatory effects by reducing nlrp3 inflammasome assembly. ac-201 is also unique in that it influences both the anabolism and catabolism of chondrocytes in vitro and has shown cartilage-sparing properties in animal studies. the study is designed to evaluate the joint structure-modifying and symptom-relieving effects, safety, and tolerability of ac-201cr in subjects with ha.


Eligibility criteria:
inclusion criteria: 1. male age 20 to 65 years, inclusive 2. diagnosis of hemophilia a or b 3. clinical diagnosis of hemophilic arthropathy in the knee(s) for at least 6 months 4. pettersson score (based on x-ray) of 0 to 4 in at least one knee within 1 year of screening 5. ipsg (2012) overall score of 3 to 9 (based on mri) in at least one knee at screening 6. is able to read, understand, and sign the informed consent form (icf), communicate with the investigator, complete study diaries, and understand and comply with protocol requirements exclusion criteria: 1. total knee replacement in the primary knee 2. presence of joint infections in the primary knee 3. knee surgery within 6 months prior to screening in the primary knee 4. intra-articular hyaluronic acid (iaha) or platelet-rich plasma (prp) injection in the primary knee within 6 months prior to screening 5. use of any of the following medications after the screening visit: 1. nsaid injection (oral nsaids including cox-2 inhibitors allowed) 2. glucosamine or chondroitin 6. history of high responder inhibitory antibodies to factor viii or factor ix clotting factor, with titer \>5 bethesda units (bu), or clinical evidence for presence of factor inhibitor 7. history of rheumatoid arthritis or gouty arthropathy 8. aspartate aminotransferase (ast) or alanine aminotransferase (alt) concentration \>2x the upper limit of laboratory normal range (uln), or bilirubin \>1.5x uln at screening 9. positive test for human immunodeficiency virus (hiv), hepatitis b virus (hbv), or tb
post-infectious irritable bowel syndrome (pi-ibs)

Conditions: Irritable Bowel Syndrome With Diarrhea

Summary: purpose: * identification of factors predisposing for post-infectious irritable bowel syndrome (pi-ibs) development after an episode of traveler's diarrhea * identification of systemic (serum) and local (biopsy) changes in infectious and immunological activity during infection and correlation with irritable bowel syndrome (ibs) symptoms, persisting after traveler's diarrhea design: * 4 study visits: before traveling, 2 weeks after traveling, 6 months after traveling, 12 months after traveling * at each study visit following investigations: blood collection, stool collection, questionnaires, rectal biopsy


Eligibility criteria:
inclusion criteria: * traveling to south-america, africa, south-east asia * 18-70 years * traveling for 1-10 weeks exclusion criteria: * chronic diarrhea * pregnant * colitis ulcerosa * morbus chrohn * ibs * coeliakie * gastrointestinal malabsorption * microscopic colitis * diverticulitis * immune deficiency * use of antibiotics/corticosteroids 2 weeks before travelling

Keywords: post-infectious irritable bowel syndrome pi-ibs
low grade chondrosarcoma versus enchondroma

Conditions: Chondroma; Chondrosarcoma

Summary: the purpose of this project is to verify possible clinical and radiological findings with regard to distinguishing enchondroma from low grade chondrosarcoma of the long bones. in addition, this study presents the outcome of patients with enchondroma and low grade chondrosarcoma of the long bones who were treated with curettage (intralesional surgery).

the investigators retrospectively review the records of 65 patients with enchondroma and 37 patients with low grade chondrosarcoma of the limbs treated by curettage between 1988 and 2014 in a single institution.

Eligibility criteria:
inclusion criteria: * chondroma or low grade chondrosarcoma of long bones exclusion criteria: * chondroma or low grade chondrosarcoma of spine and pelvis

Keywords: bone tumors chondroma chondrosarcoma
the effects of trunk exercises on upper extremity and respiratory functions in dmd

Conditions: Muscular Dystrophy, Duchenne; Upper Extremity; Respiratory Functions

Summary: the aim of this study was to investigate the effects of trunk training on trunk control, upper extremity, and pulmonary function in children with duchenne muscular dystrophy (dmd). 26 children with dmd aged 5-16 were included in the study. they were divided into two groups (study and control). the study group exercised with the trunk-oriented exercise program and the conventional exercise program under the supervision of a physiotherapist, whereas the control group underwent the conventional exercise program under the supervision of their families at home for 8 weeks. trunk control, the upper extremity function and respiratory function test were assessed before and after the 8-week exercise program in this study.

this study aimed to investigate the effects of trunk training on trunk control, upper extremity, and pulmonary function in children with duchenne muscular dystrophy. 26 children with dmd aged 5-16 were included in the study. they were divided into two groups (study and control). the study group (n=13) exercised with the trunk-oriented exercise program and the conventional exercise program under the supervision of a physiotherapist, whereas the control group (n=13) underwent the conventional exercise program under the supervision of their families at home for 8 weeks. the conventional program exercises were taught to patients and their families in the study and control groups. these exercises were performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. the conventional exercises program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles), and the trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises. trunk control was assessed using the trunk control measurement scale, the upper extremity function was assessed using performance of upper limb and respiratory function using the pulmonary function test before and after the 8-week exercise program in this study. .

Eligibility criteria:
inclusion criteria: * diagnosed with duchenne muscle dystrophy * no injuries and no neurological or orthopedic surgery in the last 6 months * no other systemic or orthopedic / neurological disorders to prevent exercise exclusion criteria: -

Keywords: duchenne muscular dystrophy trunk exercise trunk control upper extremity respiratory functions
relation of helicobacter pylori in prediabetic patients

Conditions: H.Pylori Infection

Summary: the primary objective of this study is to : find the relation between h.pylori infection and pre-diabetic patients with lipid profile . specifically, the study aims to: 1. affect of h.pylori infection in pre-diabetic patients 2. realation between pre-diabetic patient and lipid profile 3. risk factor of h.pylori infection in pre-diabetic patients d)hba1c test measures your average blood sugar level over the past 2 or 3 months. e)fasting blood sugar test. f) the igg antibody of h.pylori.

pre-diabetic state is aphase of impaired glucose tolerance 2 hours postprandial glucose (pg) in 75 g oral glucose tolerance test 140 mg/dl-199 mg/dl and/or impaired fasting glucose 100 mg/dl-125 mg/dl and/or hba1c 5.7-6.4% \[5\]. pre-diabetes is pathophysiologically similar to type ii diabetes with basic defect being insulin resistance and early beta cell failure. the amplitude of large pulses and the rapid oscillations of insulin secretion are lost in pre-diabetes. in pre-diabetes, the glycaemic excursions are usually lower than normaland there is a delay and prolongation in the second phase of insulin secretion \[6\]. recent studies have shown that colonisation with h.pylori is associated with increased development of diabetes mellitus \[7-11\]. a step towards identifying treatable causes of diabetes mellitus will aid the medical health system in developing new strategies in preventing the progression of pre-diabetes to overt diabetes mellitus .dyslipidemia is a complex disease and a major risk factor foradverse cardiovascular events \[12\]. high levels of low density lipoproteins (ldl) and low levels of high density lipoprotein (hdl) are associated with increased incidence of stoke and myocardial infarction \[13\]. dyslipidemia also plays a major role in macrovascular complications of diabetes \[14\]. there is increasing evidence for the role of h.pylori infection in the initiation, development or persistence of atherosclerosis and coronary heart disease \[15,16\]. therefore, exploring the role of treatable causes of dyslipidemia like h.pylorimay help in preventing the progression of dyslipidemia and its adverse effects.the present study aimed to assess the possible role of h.pylori infection on diabetic profile and lipid profile in pre-diabetic patients.

Eligibility criteria:
inclusion criteria: * clinical diagnosis ofpre-diabetic patients, age 30-60 years of either gender with fasting glucose 100 mg/dl-125 mg/dl and/or hba1c 5.7-6.4% exclusion criteria: * insulin dependent diabetes * hyperlipidemia
sublingual microcirculation and postoperative ileus

Conditions: Colorectal Cancer; Inflammatory Bowel Diseases; Gastrointestinal Dysfunction

Summary: the aim of this pilot study is to establish if a correlation between sub-lingual microcirculation measured by orthogonal polarization spectral (ops) imaging and symptoms of postoperative ileus exist in patients undergoing elective colorectal surgery.

aim of the study this observational study will assess whether perioperative microcirculatory changes can be correlated with symptoms associated with primary poi. primary research question is there a correlation between peri-operative microcirculatory flow measurements and the incidence of symptomatic primary poi? secondary research questions 1. is there a correlation between peri-operative microcirculatory flow measurements and the duration of symptomatic primary poi? 2. if any correlation is observed, which anatomic location (sublingual mucosa vs bowel serosa) yields microcirculatory flow measurements that are more strongly associated with the incidence and/or duration of symptomatic primary poi? 3. can either intraoperative sublingual mucosa or intraoperative bowel serosa microcirculatory flow measurements predict symptoms of primary poi? are these two anatomic locations equivalent in their ability to predict this complication?

Eligibility criteria:
inclusion criteria: * patients older than 18 yo undergoing elective laparoscopic colorectal surgery with an enhanced recovery program (erp) at the montreal general hospital exclusion criteria: * any patient who refuses enrolment